Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (656)	8/19/1999 12:03:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1494

AFTER the FACT, Hi John, The current MERZ trials for Memantine give the impression of a chronicle of history. The drug has been in use for years to treat certain types of dementia. Now MERZ will conclude three P-III clinicals to increase the market potential of this fascinating product. Clearly this data will be submitted to both the US & European governing bodies for consideration for approval. I also anticipate NTI's Aids related dementia trial will be submitted to the FDA for early consideration. With the use of MERZ's extensive P-III data and the open label usage I am convinced there is a strong speculative argument for success. In the very least the risk suggests worse case scenario of a P-III trial. Either event would be a success IMO. Given the early trial P-II successes for Nocturnal Edema I would also argue the risks are relatively low for not advancing into P-III clinicals. Clearly NTI remains a steal at these levels based on future expectations. While I thought the advances over the past year were positive. The next six to twelve months will be even more significant with at most moderate risk. PS: Funny how there is little volume. Sort of a waiting game I suppose. Buyers are waiting for lower prices. Funny however if sellers are of the hold in anticipation of the series of positive events that lie ahead then there will be a trend back to the moving average. Funny how you can guage human anticipation momentum reliably on a chart of buy & sell price interactions. I suppose I wish there were a ton of sellers down around .75 too. : ). It's not going to happen people. The expectations are way too high for that. IMO of course. BEST WISHES Jeffrey